Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Interneuron: Rehabilitation

Through a flurry of deals at year end, Interneuron Pharmaceuticals Inc. is working to rehabilitate its original business model of in-licensing products, adding value through clinical trials and regulatory milestones and then out-licensing the products to new partners.

However, the company has yet to demonstrate that the model works.

Read the full 494 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers